Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
Abstract Background The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regime...
Saved in:
Main Authors: | Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-11-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-024-03857-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association between transarterial chemoembolization refractoriness and prognosis in Chinese patients with hepatocellular carcinoma: a large retrospective cohort study
by: Qinxue Sun, et al.
Published: (2025-01-01) -
The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01) -
TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01) -
Risk Factors for Postoperative Nausea and Vomiting After TACE: A Prospective Cohort Study
by: Yuzhu Wang, et al.
Published: (2024-12-01) -
Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)